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Abstract
Knowledge about the biology and prognostic markers of neuroendocrine tumours (NET) of the lungs is scarce. As
sex steroids contribute to cell proliferation in various human tissues, we aimed at characterising the expression of
steroid receptors in a broad cohort of probes from NET of the lungs and evaluated their possible prognostic impact.
A total of 192 tumour specimens of NET of the lungs were collected, with 58 surgical specimens of typical
carcinoids, 42 of atypical carcinoids, 32 of large cell neuroendocrine carcinomas and 60 of small cell lung cancer
(SCLC). Analysis by immunohistochemistry for the following antigens was performed: estrogen receptor β (ERβ),
ERα, PR (progesterone receptor), AR (androgen receptor), Thyroid transcription factor 1 (TTF1), synaptophysin and
for chromograninA. ERβ was found to be expressed in more than 60% of tumor probes. Survival data were available
from 126 patients. In SCLC patients a subgroup analysis showed a survival benefit in the group of male patients
whose tumours expressed ERβ (p=0.008) and all SCLC patients whose tumours expressed both ERβ and
chromograninA (p=0.02). Here we could demonstrate that ERβ expression is frequent through all NET of the lungs.
Moreover, our results suggest that ERβ represents a favourable prognostic factor for SCLC male patients and all
SCLC patients whose tumors co-expressed chromogranin A.
Keywords: Estrogen receptor; SCLC; Neuroendocrine tumors of the
lung
Introduction
Primary neuroendocrine tumours (NET) of the lungs include small
cell lung cancer (SCLC), large cell neuroendocrine carcinomas
(LCNEC), atypical carcinoids (AC), and typical carcinoids (TC). These
tumors share the expression of neuroendocrine markers but present
different biological features concerning e.g. mitotic rate, development
of metastases and prognosis. The knowledge about the biology and the
prognostic markers of lung NETs is scarce and in particular it is still
unclear which tumour growth factors or pathways have significant
prognostic impact for each tumour subtype. It is well known that sex
steroid hormones play important roles in various human tissues
contributing to cell proliferation through the interaction with
intracellular receptors. To this regard, previous studies showed that a
majority of non-small cell lung cancer (NSCLC) express estrogen
receptors (ERs) [1-3] and that their growth can be stimulated by
estrogen in nude mouse xenografts [4]. Moreover, the activation of the
ER pathway has been shown to contribute to the development and
progression of NSCLC and in vitro studies showed that its inhibition
leads to tumor regression [5-7]. Androgens in androgen-receptor (AR)
positive SCLC cell lines have been shown to elicit proliferative effects
that could be counteracted by anti-androgens like flutamide or
cyproteroneacetate [8,9]. Progesteron receptor (PR) and ERα have
been described to be expressed in a small cohort of patients with lung
NET underling the challenges for differential diagnosis between these
tumours and metastases of neuroendocrine tumours from other origin
[10]. Based on these data, we aimed to characterize the protein
expression of the relevant steroid receptors in a multicentre cohort of
lung NET tissue samples from surgical specimens and evaluated their
possible use as prognostic markers.
Materials and Methods
Patient selection and Tissue Microarray (TMA) construction
Formalin-fixed and paraffin-embedded tissue blocks from surgical
specimens of patients suffering from lung NET between 1993 and 2007
were retrieved from the archives at the Institutes of Surgical Pathology,
University Hospital of Zurich, City Hospital Triemli Zurich, and
Technical University Munich. All cases were reviewed by two
pathologist (AS and DS) on full sections of a representative tumor
block and classified following the definitions of the current 2004
WHO classification for each subtype of lung NET. In particular,
carcinoid tumors were divided into typical and atypical carcinoid
based on the number of mitosis per 2 mm2 [11]. A TMA was built
using 2 tissue cores of 0.6 mm diameter for each patient in a Ventana
ES instrument (Ventana Medical Systems, Baar, Switzerland) as
previously described [12]. Additional cores of control tissue, including
Cytology & Histology Curioni-Fontecedro A, et al., J Cytol Histol 2014,5:5http://dx.doi.org/10.4172/2157-7099.1000268
Research Article Open Access
J Cytol Histol
ISSN:2157-7099 JCH, an open access journal Volume 5 • Issue 5 • 1000268
normal lung, normal tonsils as well as neuroendocrine tumors of
uterus, ileo-caecum and appendix were added in duplicates at the end.
The study was approved by the Institutional Ethical Review Board of
the University Hospital Zurich under reference number StV 29-2009.
Immunohistochemistry
For immunohistochemical (IHC) staining, 4-μm-thick paraffin
sections were cut from the TMA block and mounted on silane-coated
glass slides. The sections were stained on an automated IHC platform
(Ventana Benchmark). The following antibodies were used for ERα
(clone SP1, prediluted, Ventana, Roche), for ERβ (clone 14C8, dilution
1:150, Genetex), for AR (clone F39.4.1 Biogenex), for PR (clone 1E2,
prediluted, Ventana, Roche), for TTF1 (clone 8G7G3/1, dilution 1:50,
Dako), for Synaptophysin (clone 27G12, dilution 1:50, Novocastra)
and for Chromogranin A (CgA)  (clone DAK-A3, dilution 1:50,
Dako). Neuroendocrine markers were analysed following the last
WHO classification [11]. Biopsies were considered as positive for
TTF-1 when >50% of tumor cells were stained. To determine the
expression frequencies of ERβ, ERα, PR and AR the percentage of
positive cells was recorded and cases with nuclear staining in ≥ 5% of
cells were considered as positive for the respective antibody. The cut-
off of 5% was chosen based on data from breast cancer patients. These
patients benefit from an anti-estrogen therapy if ERβ is expressed in at
least 5% of malignant cells [13]. As for SCLC no data concerning the
prognostic or predictive value of ERβ have been shown to date, no
further scoring system was applied to our cohort of patients. Each core
was evaluated independently by two observers (A.C. and D.S.). Cases
with less than 50 evaluable cells were excluded for evaluation.
Clinical data and survival analysis
The following patient characteristics were collected: age at
diagnosis, gender, histological subtype, stage at diagnosis and survival.
Staging evaluation was based on the adjusted AJCC, TNM 7th edition
for all tumor subtypes [14,15]. The Kaplan-Meier method was used to
estimate tumor specific overall survival (OS). Tumor specific OS was
determined from the date of histological diagnosis of NET of the lungs
to the date of death from the same cancer up to 5 years follow-up.
Patients who were alive at time of the last control or died from an
unrelated death were considered as censored for OS analysis.
Categorical data were compared between groups using chi-square test
or Fisher’s exact test when appropriate. Cox-regression was used to
adjust the effect of ER beta for confounders. Continuous data were
compared between groups using the Mann-Whitney test. Statistical
analyses were performed using IBM SPSS Statistics 20.0 (SPSS Inc,
Chicago IL).
Results
Study population
A total of 192 NET tumours of the lung from 92 women and 100
men were included in the TMA and comprised 60 surgical specimens
of SCLC, 32 of LCNEC, 42 of AC and 58 of TC. For patients’
characteristics (Table 1). Immunohistochemical analysis of all markers
was available for 51/60 SCLC, 25/32 LCNEC, 32/42 AC and 44/58 TC
(Table 2). Data concerning the stage of disease was available from
47/60 SCLC, 32/32 LCNEC, 40/42 AC and 56/58 TC. Patients’ age
varied between 16 and 79 years (average of 56y).
Subtype Stage Gender (f/m) Age mean (stnd
dev)
Total
IA IB IIA IIB IIIA IIIIB IV n.a.
SCLC 9 11 8 11 1 7 13 19/41 62 (9) 60
LCNEC 9 6 4 3 6 2 2 0 10/22 63 (9) 32
AC 15 5 12 1 7 2 28/14 52 (15) 42
TC 56 2 35/23 48 (16) 58
Table 1: Clinical data: staging is reported according to the AJCC 7th edition. n.a.: not available; small-cell lung cancer (SCLC), large-cell
neuroendocrine tumors of the lung (LCNEC), atypical carcinoids (AC), typical carcinoids (TC).
Expression of neuroendocrine and lung specific markers
Neuroendocrine markers were detected at high frequency in all
tumour subtypes: Synaptophysin in 96%, CgA in 75% (both with
cytoplasmatic staining) and TTF1 in 63% of all tumour samples (with
nuclear staining), the latter in line with previously reported data
[16,17]. At least two markers were expressed in each sample. For
detailed expression data in each subtype (Table 2).
Expression of steroid receptors
ERβ was detected in 30/53 SCLC, 17/27 LCNEC, 21/33 atypical
carcinoid and 31/47 typical carcinoid samples (Table 2 and Figure 1a)
with nuclear with or without cytoplasmatic expression. ERα was
detected in 2/58 TC (Table 2 and Figure 1b) with unique nuclear
expression. Progesterone receptor was expressed in 7/53 SCLC, in 4/27
LCNEC, in 3/33 AC and in 7/47 TC, here only nuclear expression was
found (Table 2 and Figure 1c). Androgen receptor was expressed in
1/53 SCLC, in 2/27 LCNEC and in 1/33 AC. All 47 TC cases were
negative; expression was detected in the nucleus and cytoplasm (Table
2 and Figure 1d). For all markers the percentage of positive malignant
cells in the tumor samples was ≥ 5%.
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Subtype N Neuroendocrine markers and steroid receptors expression
Synaptophysin CgA TTF1 ERβ ERα PR AR
pos (%) pos (%) pos (%) pos (%) pos (%) pos (%) pos (%)
SCLC 51 48 (94%) 25 (49%) 39 (76%) 30 (59%) 0 (0%) 7(14%) 1 (2%)
LCNEC 25 23 (92%) 16 (64%) 23 (92%) 15 (60%) 0 (0%) 4 (16%) 2 (8%)
AC 32 32 (100%) 31 (96%) 15 (46%) 21 (66%) 0 (0%) 3 (9%) 1 (3%)
TC 44 44 (100%) 43 (97%) 20 (45%) 30 (68%) 2 (2%) 6 (14%) 0 (0%)
total 152 147 (96%) 115 (75%) 97 (63%) 96 (63%) 2 (1%) 20 (13%) 4 (3%)
Table 2: Immunohistochemical analysis in lung NET subtypes. Only cases with data for all markers are described. Chromogranin A (CgA);
Thyroid transcription factor 1 (TTF1); Estrogen Receptor (ER); Progestern receptor (PR); Androgen receptor (AR). Small-cell lung cancer
(SCLC), large-cell neuroendocrine tumors of the lung (LCNEC), atypical carcinoids (AC), typical carcinoids (TC).
Figure 1: Immunohistochemical staining for Estrogen receptor
(ER) β (A), ERα (B), Progesteron receptor (PR) (C) and androgen
receptor (AR) (D) in positive neuroendocrine tumors (NET) of the
lung at magnification of 10x and 40x in the bottom right square.
Association of estrogen receptor β expression with gender,
neuroendocrine and lung specific markers
ERβ expression was analysed with regard to gender, Synaptophysin,
CgA and TTF1 and no statistically significant associations were found
(resp. p=0.12, p=0.3, p=0.29, p=0.12 and p=0.13) (Table 3).
Association of estrogen receptor β expression and survival
Survival data were available for 126 patients. Survival analysis of all
patients showed a significant difference in survival between tumours
subtypes in accordance to the literature, with a 5-years tumour related
survival of 18% for SCLC, of 20% for LCNEC, of 96% for AC, of 96%
for TC. Further survival analysis was performed only for ERβ, as the
number of tumour samples positive for ERα, AR and PR was not
sufficient for statistical analysis. Neither marker nor gender did
represent an independent prognostic marker for any tumour subtype.
However, a subgroup analysis on SCLC patients, showed a survival
benefit in the subgroup of male patients whose tumours expressed ERβ
(p=0.008) compared to male and female (figure 2 resp. b and a) and a
benefit in SCLC patients whose tumours expressed both ERβ and CgA
(p=0.02) (Figure 2 resp. b, d). This results were valid for SCLC but not
for other tumour types. Moreover, in the subgroup of male SCLC
patients, a multiple Cox-regression demonstrated that ERβ expression
is associated with improved survival (hazard ratio (HR) 0.16, 95% CI
0.05 to 0.54) independently from age (HR 1.09, 95% CI 1.03 to 1.15)
and CgA (HR 1.10, 95% CI 0.44 to 2.2). Stage could not be included as
variable in the multiple Cox-regression, due to the paucity of cases in
advanced stage.
ERβ N Male/Female Synaptophysin (+) CgA (+)
TTF1
(+)
 
96 54/42 92/96 (95%) 71/96(74%)
62/96
(64%)ERβ pos
 
56 30/26 55/56 (98%) 44/56(78%)
35/56
(62%)ERβ neg
      
p value  0.12 0.29 0.12 0.13
Table 3: Analysis of all tumor types for estrogen receptor (ER) ERβ
expression associated with gender, Synaptophisin, Chromogranin A
(CgA) and Thyroid transcription factor 1 (TTF1)
Discussion
Knowledge about markers with biological relevance for NET of the
lung is scarce. In our cohort of 192 NET, we detected a protein
expression of ERβ in 63% of cases of all subtypes, while ERα, PR and
AR expression was rare (resp. 1%, 13%, 3%). The reason for frequent
ERβ expression and the mechanisms of signalling in cancer are not
entirely understood, especially in NSCLC, where data on ERs
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expression remain controversial. In NSCLC, where several pathways
have been explored, ER can interact directly with EGFR, leading to
transcription of target genes [18,19], but the role of an activated ERβ/
EGFR pathway in SCLC is to date unknown. Although EGFR
expression has been described in up to 22% of tumor samples from
SCLC patients [20-22], we detected only one case out of 51 (2%)
expressing EGFR (the analysis was performed according to Pirker [23],
data not shown). With thus suggest that alternative mechanisms are
involved in the carcinogenesis of SCLC.
Figure 2: Tumor specific overall survival analysis of SCLC patients
stratified by ERβ status. A) Overall survival data of all SCLC male
and female patients. B) Overall survival data of only SCLC male
patients. C) Overall survival data of SCLC patients negative for
Chromogranin A (CgA). D) Overall survival data of SCLC patients
with Chromogranin A (CgA) positive tumors.
Of relevance is that ERβ expression in our patients represents a
favourable prognostic marker for SCLC. In particular this is true for
two subgroups of patients: male patients and all patients whose tumors
co-expressed ERβ and CgA.
The different prognostic impact of ERβ between the male and
female patients might reflect the double role of estrogens in
carcinogenesis, as estrogens can stimulate tumor growth [24] but also
have a protective role through estrogen-receptor-β-mediated
mechanisms and stimulation of the immune system [25]. In women,
the good prognostic role of ERβ might be masked due to higher
estrogens levels compared to male patients. Concerning the positive
outcome of the subgroup of patients whose tumors co-expressed ERβ
and CgA, this result might reflect the fact that these tumors are more
differentiated. In fact CgA is more frequently elevated in well-
differentiated tumors compared to poorly differentiate ones [26];
nevertheless, CgA alone does not represent a prognostic marker, as
previousy reported. This moreover underlines the importance of this
marker in this disease and opens new perspectives for future studies.
Importantly, this is the first report of the prognostic role of ERβ in
SCLC and a confirmatory analysis is planned on a larger cohort of
patient, as our results suggest a functional role of ERβ in SCLC which
is worthwhile to further investigate.
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